Vaishali Pharma to issue shares on preferential basis for KPL acquisition

Qip At PremiumFund Raising View source PDF Explain this filing

VAISHALI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹7.96

prior close

₹8.05

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.7%+2.2% vs market

Pharmaceuticals peers, median of 154sector-0.5%+2.0% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.1

15m

+0.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5-0.7+2.2-0.5+2.0

Next day

+0.3+0.2+0.0-0.0+0.3

-1.0+0.5-1.5+0.0-1.0

-2.6-0.9-1.7-0.8-1.8

-2.6-1.0-1.6-1.4-1.2

-2.0-0.9-1.1-0.9-1.1

-8.3-2.0-6.3-2.0-6.2

15d

-18.3-6.9-11.4-4.9-13.5

-23.7-10.5-13.2-7.1-16.6

-17.7+1.5-19.3-0.2-17.5

-12.1+3.8-15.9+2.7-14.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vaishali Pharma is seeking shareholder approval to issue 61,23,000 equity shares at Rs 20 per share (including Rs 18 premium) to Kesar Pharma Limited on a preferential basis. This is a share swap for acquiring 33.24 percent additional stake in KPL, part of an overall deal worth Rs 20.42 crores. 60 percent of the deal is via share swap (Rs 12.25 crores) and 40 percent in cash. Issue price is well above the floor price of Rs 10.50. E-voting runs from Feb 14 to Mar 15, 2026.

Likely market impact

Share swap to acquire more stake in associate KPL; 4.48 percent dilution expected. No cash raised as issue is for non-cash consideration.